IDEXX Laboratories, Inc. $IDXX is Fundsmith Investment Services LTD.’s 6th Largest Position

Posted by Brian Himes on Jun 17th, 2026

Fundsmith Investment Services LTD. lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 19.5% in the fourth quarter, HoldingsChannel reports. The firm owned 553,859 shares of the company’s stock after selling 134,498 shares during the period. IDEXX Laboratories makes up about 6.9% of Fundsmith Investment Services LTD.’s portfolio, making the stock its 6th biggest holding. Fundsmith Investment Services LTD.’s holdings in IDEXX Laboratories were worth $374,702,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $26,000. Park Place Capital Corp acquired a new position in IDEXX Laboratories in the fourth quarter valued at about $29,000. WealthCollab LLC acquired a new position in IDEXX Laboratories in the second quarter valued at about $30,000. Caitong International Asset Management Co. Ltd acquired a new position in IDEXX Laboratories in the third quarter valued at about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its position in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. UBS Group decreased their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

Get Our Latest Analysis on IDEXX Laboratories

IDEXX Laboratories Trading Up 0.5%

NASDAQ IDXX opened at $573.00 on Wednesday. The stock has a market capitalization of $45.20 billion, a P/E ratio of 42.19, a PEG ratio of 3.12 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm’s 50-day moving average is $563.14 and its two-hundred day moving average is $624.14.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.